The interleukin-4 receptor plays a pivotal role in the inflammatory response and is targeted by the drug dupilimumab, a monoclonal antibody approved to treat allergic diseases such as eczema, asthma, and nasal polyps. The gene discussed is IL4R; the disease is nasal cavity polyp.